NCT04262700
Unknown
Not Applicable
Customer Outcomes & Value Experiencing A New Monitoring Technology
LifeScan Scotland Ltd2 sites in 1 country170 target enrollmentFebruary 7, 2020
ConditionsDiabetes Mellitus
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diabetes Mellitus
- Sponsor
- LifeScan Scotland Ltd
- Enrollment
- 170
- Locations
- 2
- Primary Endpoint
- A1c change from baseline after 12 weeks
- Last Updated
- 5 years ago
Overview
Brief Summary
To investigate whether novel insight features in new Blood Glucose Monitoring System (BGMs) can improve glycemic control.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
A1c change from baseline after 12 weeks
Time Frame: 12 weeks
A1c change from baseline after 12 weeks in subjects using new BGMS compared to subjects' pre-study glycemic control
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
Assessment of Blood Glucose Monitoring Devices With New Insight FeaturesDiabetes MellitusNCT02929654LifeScan267
Completed
Not Applicable
Glucose Meter StudyDiabetes MellitusNCT00782496Ascensia Diabetes Care211
Withdrawn
Not Applicable
SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 DiabetesType 1 Diabetes MellitusType 2 Diabetes MellitusNCT06719531Medtronic Diabetes1,500
Terminated
Not Applicable
Continuous Glucose Monitoring (POC) in the ICUBurnsTraumaNCT00464386United States Army Institute of Surgical Research23
Recruiting
Not Applicable
Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk FactorsCoronary Heart DiseasePhysical ActivityCardiovascular Risk FactorsNCT05969665University Hospital, Basel, Switzerland100